Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen to Apply Its PGx Tech to Drug Candidate Licensed from Mitsubishi Pharma

NEW YORK, April 13 (GenomeWeb News) - Perlegen Sciences has licensed a prospective diabetes drug from Mitsubishi Pharma to commercialize it for specific patient groups, the companies said yesterday.

 

Perlegen plans to use its genotyping technology "to improve upon the demonstrated efficacy and safety profile of MCC-555, which has been tested in over 1,000 patients" with the aim to select patients most likely to benefit, according to a company statement.

 

Under the agreement, Perlegen has exclusive rights, except for in Asia, to develop and commercialize the compound. In exchange, Mitsubishi will receive an upfront payment, and is eligible for milestone payments. Mitsubishi will exclusively license, for sales of the drug in Asia, genetic markers that Perlegen intends to find. Both companies will receive royalties from drug sales in the territory of the other party.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.